GELS (Gelteq) ROE % Adjusted to Book Value: -23.20% (As of Jun. 2025)


GELS Gelteq Ltd GELS
10 GF Score
Price $0.65
! 4 Warning Signs
View Full Analysis

What is Gelteq ROE % Adjusted to Book Value?

Gelteq GELS +2.16% 10 ROE % Adjusted to Book Value is -23.20% as of Jun. 2025. GuruFocus rates GELS with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

Gelteq's ROE % for the quarter that ended in Jun. 2025 was -39.21%. Gelteq's PB Ratio for the quarter that ended in Jun. 2025 was 1.69. Gelteq's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2025 was -23.20%.

Gelteq ROE % Adjusted to Book Value Related Terms

Gelteq ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Gelteq's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelteq ROE % Adjusted to Book Value Chart

Gelteq Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -25.19

Gelteq Semi-Annual Data
Jun20 Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25
ROE % Adjusted to Book Value Get a 7-Day Free Trial 0.00 0.00 0.00 -20.29 -23.20

GELS vs INM, LVRLF, BUDZ: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gelteq's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gelteq ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gelteq's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Gelteq's ROE % Adjusted to Book Value falls into.


GELS
10GF Score
Gelteq Ltd GELS
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gelteq ROE % Adjusted to Book Value Calculation

Gelteq's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-42.57% / 1.69
=-25.19%

Gelteq's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-39.21% / 1.69
=-23.20%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -23.20% mean?
Gelteq (GELS) has a ROE % Adjusted to Book Value of -23.20% as of Jun. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Gelteq and its competitors.
Is Gelteq's ROE % Adjusted to Book Value too high?
Gelteq's current ROE % Adjusted to Book Value is -23.20%. Overall, Gelteq has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Gelteq's ROE % Adjusted to Book Value compare to INM and LVRLF?
Gelteq's ROE % Adjusted to Book Value of -23.20% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Gelteq and its competitors. Gelteq's current ROE % Adjusted to Book Value is -23.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelteq stock overvalued right now?
Gelteq (GELS) has a current ROE % Adjusted to Book Value of -23.20%. The current ROE % Adjusted to Book Value is -23.20%. Gelteq's overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Gelteq (GELS), the current ROE % Adjusted to Book Value is -23.20% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelteq Business Description

Address 644 Chapel Street, Level 19, South Yarra, VIC, AUS, 3141
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
10GF Score

Get the complete analysis for GELS

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price